New York State Common Retirement Fund Amylyx Pharmaceuticals, Inc. Transaction History

New York State Common Retirement Fund

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	SELL	$1.62 - $2.71 $33,696 - $56,368	-20,800 Reduced 97.91%	444 $1,000
Q1 2024 May 07, 2024	SELL	$2.71 - $19.57 $6,802 - $49,120	-2,510 Reduced 10.57%	21,244 $60,000
Q4 2023 Feb 01, 2024	BUY	$12.07 - $18.46 $30,404 - $46,500	2,519 Added 11.86%	23,754 $350,000
Q3 2023 Nov 07, 2023	SELL	$18.08 - $23.45 $37,968 - $49,245	-2,100 Reduced 9.0%	21,235 $389,000
Q2 2023 Aug 07, 2023	SELL	$20.98 - $31.42 $71,248 - $106,702	-3,396 Reduced 12.7%	23,335 $503,000
Q1 2023 May 02, 2023	SELL	$27.71 - $40.93 $193,194 - $285,363	-6,972 Reduced 20.69%	26,731 $784,000
Q4 2022 Jan 30, 2023	BUY	$29.75 - $39.26 $306,335 - $404,260	10,297 Added 43.99%	33,703 $1.25 Million
Q3 2022 Nov 08, 2022	BUY	$17.15 - $30.92 $243,684 - $439,342	14,209 Added 154.5%	23,406 $659,000
Q2 2022 Aug 04, 2022	BUY	$6.85 - $19.93 $35,599 - $103,576	5,197 Added 129.93%	9,197 $177,000
Q1 2022 May 05, 2022	BUY	$12.85 - $32.9 $51,400 - $131,600	4,000 New	4,000 $51,000

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $237M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

Stay updated on New York State Common Retirement Fund with notifications on news.